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Abstract: 	  
Introduction:  The cellular retinoic acid binding protein 1 (Crabp1) promotes tumor growth and 
is expressed in adipocyte stromal cells (ASCs-L) present during lactation. One known function 
of Crabp1 is the binding and retention of retinoic acid (RA) in the cytoplasm. This can prevent 
RA regulated transcription of other genes. Research has shown that Crabp1 is also responsible 
for the inability of ASC-Ls to retain lipid. This study hoped to connect these two functions of 
Crabp1 and hypothesized that Crabp1 limits lipid accumulation through Fatty acid synthase 
(FAS) transcriptional regulation. FAS is an example of a gene that is regulated by RA. 
Methods: Luciferase assays, RT-qPCR, and Oil Red O assays were performed to study FAS 
promoter activity, mRNA levels, and lipid accumulation, respectively.  ASCs at different stages 
of mammary gland development were studied to determine the relationship between Crabp1, 
FAS, and lipid accumulation upon RA treatment.  
Results: Our results suggest that RA treatment leads to a decrease in FAS promoter activity as 
well as FAS and Crabp1 mRNA levels in ASC-Nulliparous. Furthermore, higher Crabp1 mRNA 
levels in ASC-Ls did not correlate with a decrease in FAS mRNA. ASC-Ls also showed low 
lipid accumulation in the presence of adipocyte differentiation media, suggesting that Crabp1 
regulates lipid accumulation, but not through the regulation of FAS.    
Conclusion: The mechanisms of Crabp1 in lipid regulation of ASCs remains to be determined. 
Our data show that Crabp1 does not regulate FAS though RA retention in ASC-Ls. However, our 
results are consistent with the literature in that ASC-Ls have high levels of Crabp1, but low lipid 
accumulation. Through understanding how Crabp1 is acting on the adipocytes in the mammary 
gland it can be better understood what its tumor promoting function is in PABCs.  
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Introduction:  	  
Cancer is a broad term used to describe diseases in which cells grow out of control, 
destroying body tissue. Breast cancer forms in the cells of the breast, and it is the most common 
malignancy during pregnancy [1]. Breast cancer diagnosed during pregnancy or within the first 
postpartum year is called pregnancy associated breast cancer (PABC) [2]. Approximately one in 
3,000 pregnant women are diagnosed with PABCs [1]. PABCs tend to be at an advanced stage 
when diagnosed and present larger tumors and higher percent of hormone receptor-negative 
tumors. These cancers are associated with a poor prognosis because metastasis is common. 
Mechanisms for these tumor growths are being studied and have not been fully understood [2]. 
The mammary gland is made up of epithelial cells and stromal cells. Stromal cells consist 
of pre-adipocytes, adipocytes, fibroblasts, blood vessels, inflammatory cells and extracellular 
matrix. Although breast cancer begins in the epithelium, stromal cells have a role in 
tumorigenesis [3]. Studies show that the mammary gland development has properties similar to 
breast cancer, such as reinitiation of cell proliferation, resistance to apoptosis, and angiogenesis, 
which are properties of tumor progression. The first stage of mammary gland development is 
called nulliparous. This stage describes women who have not been pregnant and have some 
epithelial cells filling the gland. During pregnancy, the second stage of development, there is 
epithelial cell proliferation. During lactation, these epithelial cells expand and differentiate into 
secretory, milk producing lobular alveoli. At this time the adipocytes decrease their lipid content 
in the gland. Then, during the involution stage, the secretory epithelium is removed by processes 
such as apoptosis. Lastly, the adipocytes refill with lipid in the regressed gland similarly to the 
nulliparous stage.  
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Changes in the microenvironments of mammary gland development are tumor 
promoting, allowing for the high mortality rate [4]. The microenvironments from different stages 
of mammary gland development differ in promoting tumors. For example, remodeling during 
lactation and involution stages has been specifically implicated in promoting PABCs [4,5].  
Lactation, a stage associated with epithelial differentiation and milk production promotes 
changes in vasculature and adipose tissue [5]. In that study, tumors from pregnant and lactating 
stages were larger than that in nulliparous and involution stages. The study notes that an increase 
in hormone levels can be causing the accelerated tumor growth during these stages. However, it 
suggests that changes in cellular composition within the lactating mammary gland 
microenvironment could be also accountable for these tumor growths. Through the study, it was 
found that adipocyte stromal cells (ASCs) from the lactating stage (ASC-Ls) of the mammary 
gland were responsible for the accelerated tumor growth. The study showed that under identical 
conditions, ASC-Ls did not accumulate lipid, unlike ASCs of nulliparous, pregnant, involuting, 
and regressed glands. ASC-Ls were found to be lipolytic, unable to accumulate lipid, and unable 
to fully differentiate. However, these cells accelerated tumor growth through angiogenesis, the 
development of new blood vessels.  
Cellular retinoic acid binding protein 1 (Crabp1) gene was one of the most differentially 
expressed in ASC-Ls [5]. The inhibition of this gene caused increased lipid accumulation and 
decreased tumor promotion, indicating that Crabp1 modulates the tumor-promoting environment 
of ASC-Ls. Crabp1 also affects the tumor promoting activity of carcinoma associated fibroblasts 
(CAFs), cells surrounding tumors in human patients. Crabp1 could also modulate tumor 
angiogenesis in CAFs. The ASCs and their expression of Crabp1 seemed to be restricted to 
lactation and cancer.  
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High levels of Crabp1 are associated with a poor prognosis of breast cancer [6]. Crabp1, 
like Crabp2 and Fabp5 (other retinoic acid binding proteins) affects retinoic acid induced cell 
growth.  Crabp1 inhibits retinoic acid (RA) signaling in breast cancer cells. This has been 
analyzed in breast tumor tissues. These findings on Crabp1 attribute this gene with a role in 
breast tumor growth. Crabp1 is key in regulation of breast cancer cell response to RA.  
  Crabp1 and Crabp2 have been highly conserved during evolution. These regulate the 
transport and metabolism of retinoic acid. Crabp1 keeps RA in the cytoplasm, thereby preventing 
it from activating gene transcription. There are two types of RA receptors, retinoic acid receptors 
(RARs) and retinoid x receptors (RXRs). In the presence of RA these can activate or suppress 
the transcription of genes that have a retinoic acid response element (RARE) in their promoter 
region. Low levels of Crabp1 expression cause higher levels of RA. Thus, this suggests that 
Crabp1 limits the availability of RA to the nuclear receptors at the cytoplasm. This works in 
contrast to Crabp2, whose expression is induced with addition of RA. The regulation of these 
transcription factors is important for gene activation in cellular differentiation [7-8].  
Other research has studied the functional differences between Crabp1 and Crabp2 [9]. 
CRABPs solubilize and protect the ligand and transport RA in the cell. Crabp2 directly interacts 
with RAR, which allows for the RAR-RA complex. Crabp1 regulates its ligand by affecting 
enzymes that metabolize RA. Thus, it might only affect the transcriptional activity of RA if the 
cell expresses these enzymes.  
 The regulation of Crabp1 during adipocyte differentiation has also been studied [10]. One 
of the factors that is involved in transcriptional regulation of Crabp1 is thyroid hormone (T3). 
The receptor interacting protein 140 (RIP140) has a role in the T3 repression of Crabp1 during 
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adipocyte differentiation. Crabp1 regulates intracellular concentration of RA and RA is thought 
to be important for the differentiation of adipocytes.  
Two proposed roles of Crabp1 are the retention of RA in the cytoplasm and RA 
metabolism into its derivatives [11]. Thus, Crabp1 is able to regulate the concentration of active 
RA able to enter the nucleus for transcriptional regulation. Cells that are sensitive to RA have 
specific regulations over Crabp1. T3 hormones have been found to regulate Crabp1 by activating 
it in pre-differentiated cells but suppressing it in cells committed to adipocyte differentiation. In 
this way T3 can stimulate adipocyte differentiation. On the contrary, RA is known to suppress 
early adipocyte differentiation. Research has found that if low levels of Crabp1 are present, RA 
can inhibit cell proliferation of precursor cells. Furthermore, in cells already committed to 
differentiation, RA in the absence of Crabp1 can facilitate differentiation.  
 Retinoids, derivatives of vitamin A or retinol, affect growth control, epithelial 
differentiation and embryonic development [12]. Retinoic acid turns a cell line into differentiated 
non-proliferating cells. Retinoic acid receptors are transcription factors that bind to the promoters 
of their target genes and activate or repress transcription depending on the presence of a 
hormone. Retinoids have antitumor activity and have been implicated in human cancer. The 
pathway for RA metabolism is a feedback system of genes activated by presence of RA. Retinoid 
receptors bind DNA on retinoic acid responsive elements (RARE). Retinoic acid treatments have 
been used against cancers since administration of retinoids has favorable impacts on tumor cells.  
 Retinoids can affect cells nearby and function intercellularly. These can regulate cell 
proliferation, differentiation and apoptosis [13]. To activate transcription in stem cells, RA inside 
the cell is first bound to Crabp2 and transported to the nucleus. Then, it binds to RARs, which 
bind to RXRs. This complex is bound to DNA and activates transcription of RA primary 
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response genes. The target genes have enhancers, which contain RAREs to which the RAR-RXR 
complex can bind. This process induces epigenetic changes, activates transcription of primary 
target genes, and induces transcription of genes, which further modify gene expression, among 
other functions. This early signaling cascade can also lead to the differentiation of stem cells. 
Because of its ability to signal cell differentiation and change patterns of gene expression in 
tumor cells, retinoids have been a component of cancer treatments. RA is also a potential agent 
for breast cancer treatment.  
 Retinoic acid has been shown to affect body fat and insulin sensitivity [14]. Retinoids 
have a role in controlling lipid and energy metabolism. RA impacts processes that affect 
mammalian adiposity such as adipogenesis, when pre-adipocytes become adipocytes, and 
lipogenesis, the process of fatty acid and triglyceride synthesis. Pathways dependent on RAR, 
such as that of RA, regulate genes encoding proteins of lipid metabolism at the transcriptional 
level. In humans, an inverse relationship has been noted between vitamin A (from which RA is 
derived) intake and adiposity. This is because retinoids, their binding proteins, and metabolizing 
enzymes play a role in the development and metabolic regulation of adipose tissues.  
Fatty acid synthase (FAS) is an enzyme that catalyzes the synthesis of fatty acids. 
Research shows how cellular sterols regulate the FAS promoter [15]. Furthermore, sterol 
regulation is mediated by binding sites for sterol regulatory element binding protein (SREBP) 
and the transcription factor Sp1. These insights on FAS promoter can be used to produce a 
plasmid with a FAS promoter, in order to study the mechanisms that drive FAS gene expression.  
Transcriptional regulatory mechanisms of FAS, specifically in the lactating mammary 
gland in goats have been studied [16]. Research provides a comparison for human, rats, and goat 
FAS promoter sequence. Studies characterized the goat FAS promoter region. The 5’ flanking 
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region of the goat FAS gene was isolated. The core region of the promoter was found to be 
conserved in humans, rats, goats, and ruminants. This region has transcription factor binding 
sites such as Sp1, NF-Y, and two sterol response element (SRE) sites. It was shown that two 
DNA binding sites for SREBP-1 are required to activate the FAS promoter. This suggested the 
binding of two sterol response elements to the FAS promoter as the SREBP-1 regulation 
mechanism of FAS levels.  
Fatty acid synthase plays a central role in lipogenesis in mammals. Researchers have 
studied the role of sterol regulatory element binding protein (SREBP) in the regulation of FAS 
promoter in vivo [17]. Findings showed that SREBP activates the FAS promoter. This study also 
suggests a role of SRE in regulation of FAS gene since it is highly conserved in rat, human, and 
goose FAS promoter sequences.  
My research builds on these findings and attempts to merge the two known functions of 
Crabp1:  Does Crabp1 regulate lipid accumulation through its ability to regulate the RA 
dependent gene FAS? We hypothesized that Crabp1 regulates the gene expression of FAS in 
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Methods: 	  
Cell Culture and Reagents 
Mammary adipose stromal cells (ASCs) were isolated from nulliparous, lactating, and 
pregnant female mice [4]. ASCs were resuspended in DMEM and plated with 10% fetal bovine 
serum (FBS) and 1% antibiotic antimyotic (Ab/Am) (Thermo Fisher Scientific). For splitting 
into a new flask, they were first washed with PBS, and trypsin was used to remove the cells from 
the culture surface. The 293T cell line was also cultured in DMEM with 10% FBS and 1% 
Ab/Am. FAS promoter reporter vector was obtained from Genecopoeia. This vector contains -
293 to -14 base pairs of the FAS human promoter [16]. Retinoic acid was purchased from Sigma.  
FAS and Crabp1 Virus Infection 
Primary cells are difficult to transfect, therefore, the 293T cell line was used for 
transduction of the virus into the primary cells. 2.5 x 105 293T cells were plated in a six well 
plate. 24 hours after plating, the cells were fed with fresh media. Then, Opti-MEM, 7.5µL 
TransIT-LT1 reagent (Mirus Bio), 600ng target DNA (FAS or FAS and shCrabp1), 400ng delta 
VPR8.2, and 200ng VSVG were added per well, for a total volume of 250µL. Two wells were 
used as canary wells and only received 242.5µL Opti-MEM and 7.5µL TransIT-LT1.  
24 hours after transfection, 1.5 x 105 ASC-N s and ASC-Ls were plated into a six well 
plate. 48 hours after transfection, the media from the 293T cells were filtered through a 0.45µM 
filter and added to ASC-Ns and ASC-Ls along with 8µg/mL polybrene.  Cells were incubated for 
four hours at 37°C after which the primary cells were fed with fresh media. 24 hours after virus 
infection, steps from the previous 24 hours were repeated for a double infection. Three days later 
the ASC-Ns and ASC-Ls were moved to a 100mm plate and 1µg/mL puromycin was added. The 
media was changed every two days and 1µg/mL puromycin was added.  
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Retinoic Acid Treatment 
 A stock of 0.1M Retinoic acid (R2625 Sigma) was prepared in DMSO and stored at -
80°C. ASC-Ns were treated with 0.1µM, 0.5µM, and 1µM RA. For –RA cells were treated with 
2µL DMSO as vehicle control. A concentration of 1µM RA was used for all following 
experiments.  
Luciferase Assay 
1000 cells per well of the ASC-N-FAS promoter and 6 x 103 cells per well ASC-L-low 
Crabp1-FAS promoter were plated in a 96 well plate.  ASC-N-FAS promoter were treated with 
1µM RA for 24hrs, 3days, or 8days. The ASC-L-low Crabp1-FAS promoter were treated with 
1µM RA for 24 hours. The luminescence was measured as described in the Secrete-Pair 
Luminescence Assay Kit protocol (Genecopoeia) using a Luminometer (Promega). The GL-S 
reading was normalized to the SEAP reading in order to detect the fold change in FAS promoter 
activity.  
Adipocyte Differentiation Assays 
For adipocyte differentiation assays, ASCs were plated in six well plates: 1.6 x 105 ASC-
N, 8.3 x 104 ASC-P, and 5.6 x 104 ASC-Ls per well. There were allowed to grow to confluence 
in DMEM supplemented with 10%FBS and 1%Ab/Am. Once confluence was reached, cells 
were treated with differentiation media: DMEM, 10%FBS, 1% Ab/Am, 0.5mM IBMX(Sigma), 
0.1 µM dexamethasone (Sigma) and 0.5 µg/mL insulin (Sigma) and 1µM RA for 14 days. Cells 
were stained with Oil Red O as follows: cells were rinsed with PBS twice, and then were fixed in 
1ml/well 10% formalin/PBS for one hour at room temperature. The wells were rinsed twice with 
dH2O and stained with 1ml per well Oil Red O for two hours. The cells were then washed with 
dH2O fifteen times. Then, the cells were washed with 1ml per well isopropanol and 300µL of 
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each well was transferred to a 96-well plate and absorbance was measured at 515nm with an 
absorbance microplate reader (BioTek ELx808). 
RT-PCR analysis 
 8.75 x 105 ASC-Ns were plated in each of four 100mm plates. These were treated with 
0.1µL, 0.5µL, and 1µM RA and collected at 24 hours. 1.6 x 105 ASC-N , 8.3 x 104 ASC-P, and 
5.6 x 104 ASC-Ls were plated in 6 well plates. ASC-N, ASC-P, and ASC-L were treated with 
1µM RA and adipocyte differentiation media (see above) or normal growth media for 14 days. 
Cell pellets were collected and total RNA was isolated and purified following the RNeasy mini 
kit (Quiagen). RNA was reverse transcribed to cDNA using an iScript cDNA synthesis kit (Bio-
Rad). Quantitative real-time PCR analysis was performed using SYBR Green (Bio-Rad) and a 
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Results: 	  
Retinoic acid treatment decreases FAS promoter activity of ASC-L-low Crabp1. To 
determine the effects of RA treatment on FAS promoter activity in stromal cells with low levels 
of Crabp1 we performed a luciferase assay. ASC-N, stromal cells isolated from nulliparous mice, 
have naturally low levels of Crabp1 protein, while ASC-L-low Crabp1 are stromal cells isolated 
during lactation that have been treated with shRNA against Crabp1 to reduce Crabp1 protein 
levels [5]. RA treatment did not appear to change the activity of the FAS promoter in ASC-Ns at 
days 1, 3, and 8 post treatment (Figure 1a). It appears that there is a slight decrease at day 8, 
however this experiment would need to be repeated to verify if it is a significant decrease. A 
luciferase assay was also performed to determine FAS promoter activity in ASC-L-low Crabp1. 
Results indicate that RA treatment led to an approximate 22% decrease in FAS promoter activity 
24 hours after transfection (Figure 1b). Taken together our data suggests that RA does not 
regulate FAS promoter activity in ASC-N but may regulate promoter activity in ASC-L-low 
Crabp1. It should be noted that this experiment was only conducted one time and needs to be 
repeated for statistical significance.   
Retinoic Acid treatment decreases FAS and Crabp1 mRNA levels in ASC-Ns. RT-PCR was 
done to measure mRNA levels in ASC-Ns treated with 1uM RA (Figure 1c). Since Crabp1 
functions to bind RA we hypothesized that treating ASC-Ns with RA might lead to an increase in 
Crabp1 mRNA.  By extension if Crabp1 is negatively regulating FAS transcription that would 
lead to a subsequent decrease in FAS mRNA levels.  Our data indicate that FAS mRNA levels 
decrease by 40% when cells were treated with RA compared to that of untreated cells. However, 
Crabp1 mRNA levels also decreased by 26% in cells treated with RA. We then speculated that 
perhaps FAS levels may not be changing but rather its function in lipid metabolism was 
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decreased.  To determine if RA was affecting proteins involved in lipid metabolism we examined 
mRNA levels of KLF2 and Pref-1. These proteins inhibit adipocyte differentiation and therefore 
are expected to decrease upon lipid accumulation in mature adipocytes. FAS may function to 
decrease the levels of these proteins.  RT-PCR data indicate that mRNA levels of KLF2 
increased 141% and mRNA levels of Pref-1 increased 150% in ASC-Ns treated with RA 
compared to untreated cells. These data suggest that RA is keeping the cells in an 
undifferentiated state and they are not capable of accumulating lipid.  This is in keeping with the 
decrease in FAS mRNA.  Taken together the data suggest that RA inhibits lipid metabolism in 
ASC-Ns but not through an increase in Crabp1. It should be noted that this experiment was only 
conducted one time and needs to be repeated for statistical significance. 
ASC-Ls prevent lipid accumulation even in the presence of adipocyte differentiation media.  
A lipid accumulation assay was done in ASC-Ns, ASC-Ls, and ASC-Ps treated with media that 
contains components designed to force adipocyte differentiation and lipid accumulation. 
Previous data has shown that ASC-Ls accumulate significantly less lipid than ASC-N and ASC-
P [5].  We hypothesized that this decrease in lipid accumulation could be due to high levels of 
Crabp1 inhibiting FAS levels.  To determine if the levels of lipid accumulation with RA 
treatment correspond with the levels of FAS and Crabp1 we performed adipocyte differentiation 
assays followed by Oil Red O staining.  Our results indicate that ASC -Ns treated with RA had 
increased lipid accumulation by 2 fold compared to untreated cells. Interestingly, ASC-Ps treated 
with RA showed a decrease in lipid accumulation by 0.5 fold. ASC-Ls showed a slight increase 
in lipid accumulation. However, this increase in lipid accumulation should be taken in context 
with the overall amount of lipid accumulation in other cell types. ASC-Ns and ASC-Ps 
accumulated a much higher amount of lipid when compared to ASC-Ls (Figure 2).  These data 
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correspond to previously published results in that ASC-Ls accumulate less lipid [5] and extends 
the research by showing that RA treatment increases lipid accumulation levels. 
Crabp1 mRNA levels are correlated with FAS mRNA levels upon retinoic acid treatment in 
cells forced to accumulate lipid. To evaluate the gene expression changes in ASCs isolated 
from multiple stages of development (ASC-pregnant, ASC-N, ASC-L) that underwent the lipid 
accumulation assay (Figure 2) we extracted the RNA from them at the end of the assay.  We 
hypothesized that changes in Crabp1 might regulate FAS levels which may then contribute to the 
cells ability to accumulate lipid. This is different from the experiments described above (Figure 
1c) in that these cells were provided reagents that force lipid accumulation.  It could be that 
Crabp1 only works to regulate FAS under those conditions.  To test this hypothesis we treated 
cells with RA and adipocyte differentiation media and performed RT-PCR (Figure 3a-d).   
Treatment of RA in cells under differentiation conditions increased Crabp1 mRNA 2.7 
fold in ASC-Ns and 14.7 fold in ASC-Ls, but decreased 0.2 fold (80%) in ASC-Ps (Figure 3a). 
Crabp2 mRNA increased 2 fold in ASC-Ns, but decreased by 0.06 fold (94%) in ASC-Ps and 
0.8 fold (20%) in ASC-Ls (Figure 3b).  This shows an inverse relationship between levels of 
Crabp1 and Crabp2 in ASC-Ls as expected due to their opposite functions in the cell [7]. RA 
treatment caused FAS mRNA levels to increase 1.4 fold in ASC-Ns and 3 fold in ASC-Ls, but a 
decrease by 0.07 fold (93%) in ASC-Ps (Figure 3c). This suggests that Crabp1 does not regulate 
FAS mRNA levels in cells forced to undergo lipid accumulation.  
Although our data do not implicate Crabp1 as a negative regulator of FAS levels, it could 
be that Crabp1 is regulating FABP4 levels. One of the proteins involved in the adipocyte 
differentiation pathway is the receptor PPARγ. The binding of another protein called TRAP220 
leads to the transcription of FABP4 and this promotes differentiation of adipocytes. We predicted 
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that Crabp1 could be involved in this pathway to regulate lipid accumulation in ASC-Ls because 
it also interacts with TRAP220 [20]. To determine if Crabp1 regulated FABP4, we measured 
FABP4 mRNA levels in ASC-Ns treated with both RA and adipocyte differentiation media. 
Levels of FABP4 mRNA levels increased 1.4 fold in ASC-Ns and 5 fold in ASC-Ls, but 
decreased by 0.08 fold in ASC-Ps (Figure 3d).  Taken together, our data suggest that the stages 
of the mammary gland respond to RA treatment differently when exposed to adipocyte 
differentiation media. In addition, our data suggest that Crabp1 does not negatively regulate FAS 
levels. Increased levels of FABP4 and FAS in ASC-Ls also suggest that high levels of Crabp1 
will not necessarily lead to a decrease in lipid synthesis. It should be noted that this experiment 
was only conducted one time and needs to be repeated for statistical significance. 	  	  	  	  	  	  	  	  	  	  	  
 
 
	   18	  
Discussion:  	  
High levels of Crabp1 in the mammary gland are associated with poor prognosis in 
PABCs. Previous research indicates that Crabp1 promotes tumor growth and that it prevents lipid 
accumulation. However it is unclear how Crabp1 prevents lipid accumulation.  This study was 
conducted to begin to understand this mechanism. In this report we have shown that treating cells 
with RA leads to a decrease in FAS promoter activity of ASC-L-low Crabp1, but does not appear 
to change FAS promoter activity in ASC-Ns. It is interesting to note that treatment of ASC-L-low 
Crabp1 cells with RA decreased the FAS promoter activity by 22%.  It would be worthwhile to 
return to those cells to ensure that Crabp1 levels are in fact still low and do not have restored 
levels of Crabp1.  If this was the case we are tempted to speculate that Crabp1 may be regulating 
the FAS promoter. Additional experiments would be needed to ensure the Crabp1 levels as well 
as performing luciferase assays with ASC-Ls to measure FAS promoter activity in cells that 
normally have high levels of Crabp1.   
We also report that retinoic acid treatment also leads to decreased FAS and Crabp1 
mRNA levels in ASC-Ns, suggesting that RA inhibits lipid metabolism, but not through 
increasing Crabp1. However, ASC-Ls (cells with normally high Crabp1 levels) showed a slight 
increase in lipid accumulation when treated with RA, but extremely low lipid accumulation 
compared to other cell types, corroborating previously published research [5]. ASC-Ns (cells 
with low Crabp1) had increased lipid accumulation when treated with RA. These results are 
consistent with previous research and suggest that the role of Crabp1 binding to RA may not be 
involved in its ability to regulate lipid accumulation. Furthermore, Crabp1 mRNA levels 
correlated with FAS mRNA levels upon RA treatment in cells forced to accumulate lipid, 
suggesting that Crabp1 is not a negative regulator of FAS levels under those conditions.  
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The data reported herein do not support the hypothesis that Crabp1 regulates lipid 
accumulation through the regulation of the RA dependent gene FAS. It is possible that Crabp1 is 
able to regulate lipid accumulation independent of its ability to bind to RA, possibly through 
different domains on the protein. This is a plausible explanation for why RA dependent genes 
were affected by RA treatment, but not in a Crabp1 dependent matter.  It should be noted that 
RA has been shown to inhibit lipid metabolism and adipogenesis [19]. Others studies have 
shown that RA does not decrease lipid accumulation [22]. Therefore lipid metabolism and lipid 
accumulation could involve distinct pathways and Crabp1 could be acting solely to regulate lipid 
accumulation. Crabp1 binding and retention of RA would therefore not affect FAS and FABP4 
levels. However, whether or not Crabp1 inhibits lipid accumulation through regulation of RA 
still needs to be fully determined.  
In order to fully address the hypothesis we must first return to the functions of Crabp1.  It 
is known to bind and sequester RA in the cytoplasm and thereby prevent transcriptional 
activation of RA responsive genes [6].  It also functions to prevent lipid accumulation [5].  
Rather than try to determine if Crabp1 regulates lipid accumulation by binding to RA it would 
first be important to determine how Crabp1 accomplishes these two functions.  Crabp1 binds to 
RA at the lipocalin/ cytosolic fatty-acid binding protein family domain [21]. However the 
domain(s) responsible for the lipid accumulation function are unknown.  It would be interesting 
to perform experiments that determine the structure-function relationship of the protein by 
overexpressing truncated protein and performing lipid accumulation assays.  This would be the 
next step in our understanding of the role of Crabp1 in lipid accumulation as well as if this 
function is important in its role as a tumor promoter. 
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It is important that the known functions of Crabp1 in the cell be understood in order to 
study how Crabp1 promotes tumor growth, particularly in ASC-Ls. Research has shown that 
PABCs diagnosed during lactation are associated with poor prognosis [2,5]. Furthermore, high 
levels of Crabp1 are associated with poor prognosis in breast cancer [6]. Knowing the RA and 
lipid associated functions of Crabp1, and that it plays a role in tumor promotion in PABCs, led 
us to investigate its role in FAS expression in the presence of RA treatment. Although our results 
suggest that Crabp1 is not regulating FAS expression, these are consistent with previous research 
in that ASC-Ls fail to accumulate lipid in comparison to other cell types. Also, our results 
suggest that RA increases lipid accumulation in ASC-Ns and slightly on ASC-Ls, but not ASC-
Ps, thus it could be dependent upon the microenvironment of the mammary gland at particular 
stages. It is probable that high levels of Crabp1 in ASC-Ls decreased the impact of this RA 
function. However, further understanding of Crabp1 structure-function relation is needed to 
investigate its lipid regulation function. The finding of mechanisms present during this stage of 
mammary gland development and how these can promote tumorigenesis, could allow us to 
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Figure 1: Retinoic acid treatment decreases FAS promoter activity of ASC-L-low Crabp1 
and decreases FAS and Crabp1 mRNA levels in ASC-Ns. (a) Luciferase assay of ASC-Ns 
transfected with the FAS promoter. These were treated with 1µM RA and were collected at 
24hrs, 3 days, and 8 days. Treated cells were compared to untreated cells (-RA). (b) ASC-L-low 
Crabp1 cells transfected with the FAS promoter were treated with 1µM RA. RA treated ASC-L-
low Crabp1 were compared to untreated cells. (c) RT-PCR was used to measure mRNA levels of 
several genes in transfected ASC-Ns expressing the FAS promoter. Data was normalized to 
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Figure 2: Retinoic acid treatment effects on lipid accumulation are stage dependent. 
Quantification of Oil Red O staining of ASC-Ns, ASC-Ps, and ASC-Ls treated with adipocyte 
media and 1µM RA. Absorbance was measured at 510nm. RA treated cells are compared to 
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Figure 3: Retinoic acid treatment leads to different levels of gene expression dependent on 
the developmental stage of the cells. (a-d) RT-PCR using ASC-N, ASC-P, and ASC-Ls treated 
with adipocyte differentiation media and 1µM RA. Data was normalized to GAPDH in the 
presence of adipocyte media and 1µM RA and is represented as fold change in comparison to 
untreated (-RA) cells. The horizontal line indicates untreated cells set to one.  Bars above the line 
indicate an increase in expression and bars below the line indicate a decrease in expression 
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